Interleukin-6: Still crazy after all these years

Critical Care Medicine

Volumn 34, Issue 10, 2006, Pages 2690-2691

  O'Malley, Kerri ^a   Moldawer, Lyle L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cecal ligation and puncture; Cytokines; Intereukin 6; Liver; Sepsis

Indexed keywords

INTERLEUKIN 6;

BACTERIAL TRANSLOCATION; BURN; CHOLESTASIS; CRITICALLY ILL PATIENT; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EDITORIAL; HUMAN; INFLAMMATION; LIVER INJURY; LIVER REGENERATION; LIVER TOXICITY; MORTALITY; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SEPSIS; SEPTIC SHOCK; STEATOSIS; SURVIVAL; TREATMENT OUTCOME;

ANIMALS; FEMALE; HEPATOCYTES; INTERLEUKIN-6; LIVER DISEASES; MALE; MICE; MICE, KNOCKOUT; SEPSIS;

EID: 33748805762     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000239424.59338.2F     Document Type: Editorial

References (21)

1. Taub R: Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 2004; 5:836-847
2. Schindler R, Mancilla J, Endres S, et al: Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75:40-47
3. Tracey KJ, Lowry SF, Fahey TJ III, et al: Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 1987; 164:415-422
4. Fischer E, Marano MA, Barber AE, et al: Comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates. Am J Physiol 1991, 261:R442-R452
5. Espat NJ, Auffenberg T, Rosenberg JJ, et al: Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response. Am J Physiol 1996, 271:R185-R190
6. Sosman JA, Aronson FR, Sznol M, et al: Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: Reversible dose-limiting neurological toxicity. Clin Cancer Res 1997; 3:39-46
7. Dinarello CA, Cannon JG, Mancilla J, et al: Interleukin-6 as an endogenous pyrogen: Induction of prostaglandin E2 in brain but not in peripheral blood mononuclear cells. Brain Res 1991; 562:199-206
8. Remick DG, Bolgos GR, Siddiqui J, et al: Six at six: Interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002; 17:463-467
9. Patel RT, Deen KI, Youngs D, et al: Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg 1994; 81:1306-1308
10. Abraham E, Anzueto A, Gutierrez G, et al: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351:929-933
11. Abraham E, Glauser MP, Butler T, et al: p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997; 277:1531-1538
12. Kopf M, Baumann H, Freer G, et al: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368:339-342
13. Dalrymple SA, Slattery R, Aud DM, et al: Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect Immun 1996; 64:3231-3235
14. Leon LR, White AA, Kluger MJ: Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am J Physiol 1998, 275:R269-R277
15. Remick DG, Bolgos G, Copeland S, et al: Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect Immun 2005; 73:2751-2757
16. Wang Q, Fang CH, Hasselgren PO: Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice. Am J Physiol Regul Integr Comp Physiol 2001; 281:R1013-R1023
17. Deutschman CS, Cereda M, Ochroch EA, et al: Sepsis-induced cholestasis, steatosis, hepatocellular injury, and impaired hepatocyte regeneration are enhanced in interleukin-6 -/- mice. Crit Care Med 2006; 34:2613-2620
18. Riedemann NC, Neff TA, Guo RF, et al: Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol 2003; 170:503-507
19. Gennari R, Alexander JW: Anti-interleukin-6 antibody treatment improves survival during gut-derived sepsis in a time-dependent manner by enhancing host defense. Crit Care Med 1995; 23:1945-1953
20. Vyas D, Javadi P, Dipasco PJ, et al: Early antibiotic administration but not antibody therapy directed against IL-6 improves survival in septic mice predicted to die on basis of high IL-6 levels. Am J Physiol Regul Integr Comp Physiol 2005; 289:R1048-R1053
21. May LT, Neta R, Moldawer LL, et al: Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo. J Immunol 1993; 151:3225-3236